Αποτελέσματα Αναζήτησης
1 Μαΐ 2018 · Dose-Dense AC (DD-AC, Doxorubicin + Cyclophosphamide) + TH (Taxol® + Herceptin®) is a Chemotherapy Regimen for Breast Cancer - early stage. How does Dose-Dense AC + TH work? Doxorubicin, cyclophosphamide, and paclitaxel are designed to kill or slow the growth of cancer cells.
This protocol is part of the AC-TH regimen: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Link to Breast adjuvant AC-TH overview; Link to Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly; Drug status: Docetaxel is on the PBS general schedule. Trastuzumab is PBS authority
8 Οκτ 2014 · Based on these data, TC is considered a standard regimen for adjuvant therapy for node-negative or low-risk node-positive breast cancer. 25 For high-risk breast cancer, good evidence suggests that four cycles of TC is inferior to sequential AC-T (even when concurrent anthracycline is added to TC). 26, 27 Although AC-T has superior breast cancer ...
7 Δεκ 2022 · The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings.
AC is a combination of two chemotherapy drugs used to treat breast cancer. It takes its name from the initials of these drugs: • doxorubicin (also known as Adriamycin) • cyclophosphamide 2. Who might be offered AC chemot herapy? AC chemotherapy can be used to treat primary breast cancer – breast cancer that hasn’t
You must not become pregnant during treatment with AC-T and must use an effective method of contraception. You should take appropriate contraceptive measures during and up to 12 months after cessation of treatment. If pregnancy occurs during your treatment, you must inform your doctor immediately.
11 Απρ 2024 · Sequential Adriamycin-cyclophosphamide therapy with paclitaxel or docetaxel (AC-T) was declared by a 2015 review to likely be the most effective treatment regimen of early-stage breast cancer regardless of hormone status.
